- Home
- NCPL vs OGEN Comparison
NCPL vs OGEN Comparison
Compare NCPL & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- OGEN
- Stock Information
- Founded
- NCPL 1984
- OGEN 1996
- Country
- NCPL United States
- OGEN United States
- Employees
- NCPL N/A
- OGEN N/A
- Industry
- NCPL Investment Managers
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- OGEN Health Care
- Exchange
- NCPL Nasdaq
- OGEN Nasdaq
- Market Cap
- NCPL 4.3M
- OGEN 4.6M
- IPO Year
- NCPL N/A
- OGEN N/A
- Fundamental
- Price
- NCPL $4.08
- OGEN $3.61
- Analyst Decision
- NCPL
- OGEN
- Analyst Count
- NCPL 0
- OGEN 0
- Target Price
- NCPL N/A
- OGEN N/A
- AVG Volume (30 Days)
- NCPL 568.1K
- OGEN 632.7K
- Earning Date
- NCPL 07-28-2025
- OGEN 08-08-2025
- Dividend Yield
- NCPL N/A
- OGEN N/A
- EPS Growth
- NCPL N/A
- OGEN N/A
- EPS
- NCPL N/A
- OGEN N/A
- Revenue
- NCPL $812,612.00
- OGEN N/A
- Revenue This Year
- NCPL N/A
- OGEN N/A
- Revenue Next Year
- NCPL $101.16
- OGEN N/A
- P/E Ratio
- NCPL N/A
- OGEN N/A
- Revenue Growth
- NCPL N/A
- OGEN N/A
- 52 Week Low
- NCPL $1.41
- OGEN $3.12
- 52 Week High
- NCPL $11.90
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- NCPL 68.27
- OGEN 38.03
- Support Level
- NCPL $3.82
- OGEN $3.41
- Resistance Level
- NCPL $5.75
- OGEN $4.85
- Average True Range (ATR)
- NCPL 0.63
- OGEN 0.62
- MACD
- NCPL 0.15
- OGEN -0.04
- Stochastic Oscillator
- NCPL 53.87
- OGEN 23.11
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.